 |
BIG-PHARMA: JUST FOR PROFIT?
source: www.worldbank.org/hnp/hsd/
documents/LOCALPRODUCTION.pdf
www.worldcivilsociety.org/REPORT/
EN/06/16-jul-02/summ_16.21.html
|
|
The global pharmaceutical market growth is accelerating, with the vast majority of the market dominated by the developed countries of Europe, Japan and the United States…- in 2002, total global market had quadrupled and was about US$ 424 billion;
- developing countries, particularly in Africa, are not contributing to this growth in market;
- many Asian countries will increase their share of the global pharmaceutical market over the next few years.
Profits to a few… | | % of the global market | | North America, Europe, & Japan | 83 | | Latin America | 6 | | Africa, India, Australasia | 4.4 |
In developing countries there is a great disparity between the demand for medicines to treat endemic diseases and the lack of purchasing power…- two decades ago, about 25% of world drug production of about US$100 billion was accounted for by developing and middle income countries. Total production by value in the European countries, USA and Japan accounted for about $70 billion while production in South and Central America, Africa, Middle East and Asia accounted for just over US$11 billion;
- nonetheless, developing countries imported about 32% of the world’s total pharmaceutical imports. Developing countries imported 7 times more drugs than they exported;
- by 1990, the share of world pharmaceutical production of Africa and Latin America declined while that of Asia increased only 18% of world production of pharmaceuticals was located in the developing and middle income countries.
|
